OphtiMed Rx

Pioneering a groundbreaking treatment for dry Age-related Macular Degeneration (AMD) by targeting aging processes to address the unmet need, halt disease progression, and prevent vision loss.

Health Tech & Life Sciences
registrar: מחוסלת מרצון
Seed Afula, Israel Founded 2021
Last updated 2026-07-19
Total raised
$1.3M
Last: Undisclosed Round 2021-11
Stage
Seed
Founded
2021
Headcount
4
HQ
Afula, Israel
Sector
Health Tech & Life Sciences

About

OphtiMed Rx is a preclinical startup developing an anti-aging therapy for dry AMD, a leading cause of global blindness. The company's innovative drug targets cellular aging (senescence) in AMD, offering a disruptive approach to halt its progression. OphtiMed Rx holds a use patent for treating retinal degenerative diseases with its compound or functional derivatives, granted in the USA, EU, and Israel, with a new patent protecting a novel formulation for ocular administration currently underway. The company is conducting comprehensive preclinical research and development studies, with plans to be ready for Phase I clinical trials by late 2025 or mid-2026.

Funding history · 1 round · $1.3M total

2021-11
Seed $1.3M
Israel Innovation Authority (IIA)Mor Research ApplicationsGO Innovation GroupWomen TechEU programGalil Ofek VenturesRunYoung organization

Headcount over time

From 3 (2022-04) to 4 (2025-04) · +1 (+33%) · 6 points · source: Finder history + radar grounding
50 2022-04 2025-04

Q&A

What is OphtiMed Rx's primary focus?
OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease leading to blindness.
When was OphtiMed Rx founded?
OphtiMed Rx was founded in November 2021.
What is the total funding raised by OphtiMed Rx to date?
OphtiMed Rx has raised a total of $1,300,000.
Which investor participated in OphtiMed Rx's funding round in November 2021?
G.O Innovation participated in OphtiMed Rx's funding round in November 2021.
What is the current employee count for OphtiMed Rx?
OphtiMed Rx has 1-10 employees.
What is OphtiMed Rx's current product stage?
OphtiMed Rx is currently in the R&D product stage.
Does OphtiMed Rx hold any patents?
Yes, OphtiMed Rx holds 1 patent.
Where is OphtiMed Rx headquartered?
OphtiMed Rx is headquartered in Afula, Israel.

Team · 1

Founder · Co-founder and CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business model
B2B

Highlights

1 PatentsVerified

Tags

pharmaceuticalspharma-companiesdrug-discoveryprivate-investorsophthalmologyinvestorseye-diseasesdrug-development
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)